Cargando…

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia

Systemic light chain amyloidosis is a rare and life-threatening disorder, for which accurate risk stratification is crucial. Current cardiac staging systems (MAYO2004, MAYO3b, and MAYO2012) are mainly based on biomarkers, which have uncertain reliability in the context of atrial fibrillation, arrhyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dittrich, Tobias, Benner, Axel, Kimmich, Christoph, Siepen, Fabian aus dem, Veelken, Kaya, Kristen, Arnt V., Bochtler, Tilmann, Katus, Hugo A., Müller-Tidow, Carsten, Hegenbart, Ute, Schönland, Stefan O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601086/ https://www.ncbi.nlm.nih.gov/pubmed/30655373 http://dx.doi.org/10.3324/haematol.2018.205336

Ejemplares similares

Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
por: Hein, Selina, et al.
Publicado: (2021)

Wild-type transthyretin amyloidosis in female patients
por: Kristen, Arnt V, et al.
Publicado: (2015)

Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis
por: Arenja, Nisha, et al.
Publicado: (2019)

Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis
por: Hein, Selina J, et al.
Publicado: (2021)

Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy
por: Aurich, Matthias, et al.
Publicado: (2023)

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up
por: Hegenbart, Ute, et al.
Publicado: (2017)

Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis
por: Ochs, Marco M., et al.
Publicado: (2017)

Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
por: Siepen, Fabian aus dem, et al.
Publicado: (2015)

T1 mapping: useful for treatment monitoring in patients with senile systemic amyloidosis?
por: dem Siepen, Fabian aus, et al.
Publicado: (2014)

Non-invasive risk stratification of patients with TTR amyloidosis
por: Scherer, Katrin A, et al.
Publicado: (2013)

Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms
por: Korosoglou, Grigorios, et al.
Publicado: (2021)

Comparison of late gadolinium enhancement patterns in different forms of cardiac amyloidosis
por: Kammerer, Rebekka, et al.
Publicado: (2013)

Thickness of the midventricular left ventricular wall is predictive of survival in different forms of cardiac amyloidosis
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis
por: Hoerbrand, Isabel A., et al.
Publicado: (2022)

MR-Neurography of the sural nerve in patients with hereditary amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Quantitative MR-neurographic parameters can determine and specify nerve injury in amyloid related polyneuropathy
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement
por: Berghaus, Natalie, et al.
Publicado: (2022)

Deferred autologous stem cell transplantation in systemic AL amyloidosis
por: Manwani, Richa, et al.
Publicado: (2018)

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis
por: Granzow, Martin, et al.
Publicado: (2017)

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
por: Liebers, Nora, et al.
Publicado: (2022)

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
por: Korell, Felix, et al.
Publicado: (2023)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
por: Seckinger, Anja, et al.
Publicado: (2018)

Cardiac magnetic resonance strain imaging in systemic light chain amyloidosis
por: Andre, Florian, et al.
Publicado: (2014)

Non-invasive measurement of myocardial extracellular volume using T1 mapping as a novel biomarker of diffuse fibrosis in dilated cardiomyopathy
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

Assessment of myocardial strain in patients with myocarditis by cardiac magnetic resonance imaging
por: Andre, Florian, et al.
Publicado: (2014)

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report
por: Feurstein, Simone, et al.
Publicado: (2022)

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2022)

Diffuse myocardial fibrosis in early forms of dilated cardiomyopathy: insights from T1 mapping cardiovascular magnetic resonance
por: aus dem Siepen, Fabian, et al.
Publicado: (2013)

Right ventricular function in dilated cardiomyopathy: relation to location of focal myocardial fibrosis
por: Abdelrazek, Mohamed A, et al.
Publicado: (2013)

Extracellular volume assessed by CMR T1-mapping correlates with histologically determined amount of diffuse fibrosis in DCM
por: aus dem Siepen, Fabian, et al.
Publicado: (2014)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)
por: Yilmaz, A., et al.
Publicado: (2021)

Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
por: Radamaker, Lynn, et al.
Publicado: (2021)

MRI detected mass decrease in patients with amyloidosis after treatment with green tea: a one year follow-up study
por: Buss, Sebastian, et al.
Publicado: (2012)

A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma
por: Dittrich, Tobias, et al.
Publicado: (2022)

Flow cytometry‐based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis
por: Lisenko, Katharina, et al.
Publicado: (2016)

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis
por: Radamaker, Lynn, et al.
Publicado: (2019)

Z-score mapping for standardized analysis and reporting of cardiovascular magnetic resonance modified Look-Locker inversion recovery (MOLLI) T1 data: Normal behavior and validation in patients with amyloidosis
por: Kranzusch, Riccardo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1o3jfmnlr5h184cqrnn03sfv7g